Sarepta's Elevidys Faces 'Little'Pressure After Regenxbio Data, Wedbush Says
15 maj, 17:29
11:29 AM EDT, 05/15/2026 (MT Newswires) -- Sarepta Therapeutics'(SRPT) Elevidys is put under a "little"pressure on Regenxbio's (RGNX) positive trial data in Duchenne muscular dystrophy, Wedbush Securities said in a note Friday.
The note pointed to statistically significant correlation between microdystrophin expression and functional improvement in the trial of RGX-202, and should benefit all microdystrophin gene therapy programs/products.
"We see no other big impact on Elevidys,"it said. "We do not believe that the relatively small patient number in RGNX's study allows for a fair comparison of microdystrophin expression."
The report also said the regulatory pathway for RGX-202 remains to be defined.
Wedbush kept its outperform rating and a $35 price target.
Price: 18.12, Change: -0.56, Percent Change: -3.00
Ämnen i artikeln
Sarepta's Elevidys Faces 'Little'Pressure After Regenxbio Data, Wedbush Says
15 maj, 17:29
11:29 AM EDT, 05/15/2026 (MT Newswires) -- Sarepta Therapeutics'(SRPT) Elevidys is put under a "little"pressure on Regenxbio's (RGNX) positive trial data in Duchenne muscular dystrophy, Wedbush Securities said in a note Friday.
The note pointed to statistically significant correlation between microdystrophin expression and functional improvement in the trial of RGX-202, and should benefit all microdystrophin gene therapy programs/products.
"We see no other big impact on Elevidys,"it said. "We do not believe that the relatively small patient number in RGNX's study allows for a fair comparison of microdystrophin expression."
The report also said the regulatory pathway for RGX-202 remains to be defined.
Wedbush kept its outperform rating and a $35 price target.
Price: 18.12, Change: -0.56, Percent Change: -3.00
Ämnen i artikeln
Aktieanalys
Rapporter i urval
Aktieköp
Aktieanalys
Rapporter i urval
Aktieköp
Marknadsöversikt
1 DAG %
Senast
1 mån
